MOLECULAR DETERMINANTS OF PAIRED HELICAL FILAMENT ASSEMBLY AND ITS THERAPEUTIC IMPLICATIONS IN ALZHEIMERS-DISEASE

Citation
Cm. Wischik et al., MOLECULAR DETERMINANTS OF PAIRED HELICAL FILAMENT ASSEMBLY AND ITS THERAPEUTIC IMPLICATIONS IN ALZHEIMERS-DISEASE, International review of psychiatry, 7(3-4), 1995, pp. 299-338
Citations number
212
Categorie Soggetti
Psychiatry
ISSN journal
09540261
Volume
7
Issue
3-4
Year of publication
1995
Pages
299 - 338
Database
ISI
SICI code
0954-0261(1995)7:3-4<299:MDOPHF>2.0.ZU;2-5
Abstract
Studies of Alzheimer's disease have pointed to loss of the normal micr otubule associated protein tau and accumulation of pathological paired helical filaments as strong discriminators for cognitive impairment. The most likely explanation is that the redistribution of tau protein into PHFs is associated with a failure of axonal transport in cortico- cortical association circuits through failure to maintain axonal tubul in in the polymerized state within pyramidal cells. Current understand ing of and attempts to translate the key pathogenetic steps in tau pat hology as they occur in the human brain are reviewed. Although the pho sphorylation hypothesis has dominated the application of molecular and cell biological methods, there are substantial difficulties with this account when it has been tested in clinico-pathological studies. The present review develops a more pragmatic view of PHF assembly, that it is in principle an amyloidosis, since more than 80% of the tau protei n found PHFs is in the form of detergent insoluble protease-resistant polymers of molecules which have undergone substantial proteolytic pro cessing in the course of polymerization. These molecules have also und ergone a characteristic conformational shift in the course of polymeri zation, and acquire binding sites for planar dyes. The theoretical sta nce which best fits this data is that which has been proposed in the P rion diseases. A variety of factors may act to initiate a pathological conformational change which is then propagated because of the capacit y of the modified form of the molecule to seed the polymerization of t he normal form. Whatever the ultimate causes, the process can be shown to progress exponentially in the human brain. Pharmaceutical blockade of pathological redistribution of tau protein into PHFs would represe nt a desirable pharmaceutical target, since it is likely to represent a major component of the final common molecular substrate of clinical dementia of the Alzheimer-type.